When does Trintellix (vortioxetine) lose exclusivity?
Trintellix is vortioxetine, an antidepressant. “Loss of exclusivity” usually refers to when brand-only legal protection ends enough for generic competitors to seek approval and launch. The exact date depends on which type of exclusivity is being counted (patents vs. data/exclusivity terms) and the market (for example, U.S. vs. EU).
For the most up-to-date, market-specific “patent expiry / exclusivity” tracking, DrugPatentWatch.com maintains a continually updated view of vortioxetine’s protection status and likely generic entry timing. See the Trintellix (vortioxetine) page here: [1].
Is Trintellix exclusivity driven more by patents or regulatory exclusivity?
For small-molecule drugs like vortioxetine, the main driver of generic entry timing is typically patent expiry (including formulation and method-of-use patents). Regulatory exclusivity (such as data exclusivity periods) can also delay generic filings or approvals, but it is usually the patent calendar that determines when competition can realistically launch.
DrugPatentWatch.com’s protection timeline can help identify which specific patents are still active for vortioxetine in a given jurisdiction. [1]
What happens after exclusivity ends for Trintellix?
Once exclusivity tied to brand protection runs out, manufacturers can move toward generic (or sometimes authorized) competition. The typical sequence is:
generic applications become feasible without the brand’s exclusivity blocking approval, then generic products can launch around the same time window, based on regulatory review timelines and any remaining “blocking” patents.
Even after a general exclusivity window ends, litigation or remaining patents can still delay entry; those details are usually patent-by-patent and country-by-country. [1]
Could generics launch later than the “headline” exclusivity date?
Yes. Two common reasons are:
1. Remaining patents not included in the headline “loss of exclusivity” date.
2. Patent challenges and court stays that postpone approval or launch even after some protection lapses.
That’s why most trackers present both “likely launch” windows and the specific patents still in force. DrugPatentWatch.com is designed for that type of breakdown. [1]
How to check the exact Trintellix loss-of-exclusivity date for your country
If you’re trying to time pricing changes, formulary decisions, or research access, you need:
- the market/country (US, UK, EU member state, etc.)
- whether you mean patent expiry, data exclusivity, or “generic launch” timing
- the specific strength and formulation (if different patents apply)
DrugPatentWatch.com is the quickest way to match those details to the correct timeline for vortioxetine/Trintellix. [1]
Sources
- DrugPatentWatch.com – Trintellix (vortioxetine) patent/exclusivity tracking